Literature DB >> 9830629

Overview of prognostic factors in non-Hodgkin's lymphoma.

D F Moore1, F Cabanillas.   

Abstract

The non-Hodgkin's lymphomas are a biologically heterogeneous group of diseases with varying clinical presentations and outcomes. A number of studies have identified variables that carried independent prognostic significance. Although several staging systems had evolved that incorporated these prognostic variables, they were still unable to predict outcome. Ideally, the object of a staging system is to predict the likelihood of treatment response, time to progression or disease-free survival, and overall survival, and to provide a way to compare the outcome of similar groups of patients among various clinical trials. The need for such a system led to the creation of prognostic models such as the M.D. Anderson Tumor Score and, more recently, the International Prognostic Index. These prognostic models may identify those patients at highest risk for treatment failure, thereby identifying those patients who may require different therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830629

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  5 in total

1.  Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.

Authors:  M el-Far; M Fouda; R Yahya; H el-Baz
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

2.  Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.

Authors:  Pieter de Witt; Deborah J Maartens; Thomas S Uldrick; Gerhard Sissolak
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

3.  Clinicopathological Characteristics and Molecular Phenotypes of Primary Hepatic Lymphoma.

Authors:  Ai-Yan Xing; Xin-Zhe Dong; Liu-Qing Zhu; Long Liu; Dong Sun; Sen Guo
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

Review 4.  Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.

Authors:  Miriam Sharpe; Stephanie E Easthope; Gillian M Keating; Harriet M Lamb
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma.

Authors:  Ting Lu; Yan Liu; Shuang Yu; Congcong Yin; Peng Li; Jingjing Ye; Daoxin Ma; Chunyan Ji
Journal:  Oncotarget       Date:  2016-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.